

## Mouse anti-human Annexin 1 Monoclonal Antibody (Clone 29)

### REFERENCES AND PRESENTATIONS<sup>1</sup>

- **ready-to-use (ml)**  
MAD-000425QD-3  
MAD-000425QD-7  
MAD-000425QD-12
- **MD-Stainer presentations<sup>2</sup>**  
MAD-000425QD-3/V  
MAD-000425QD/V
- **concentrated**  
MAD-000425Q - 1:50 recommended dilution

### COMPOSITION

Anti-human Annexin 1 mouse monoclonal antibody purified from serum and prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide

**INTENDED USE** : Immunohistochemistry (IHC) on paraffin embedded tissues. Not tested on frozen tissues or Western-Blotting

**CLONE:** 29

**Ig ISOTYPE:** mouse IgG1

**IMMUNOGEN:** Aminoacids 1-346 of bovine annexin

**SPECIES REACTIVITY:** In vitro diagnostics in humans. Not tested in other species

**DESCRIPTION AND APPLICATIONS:** Annexin I (a.k.a. lipocortin-1 or calpactin II) is a 38kDa protein that is part of a calcium-dependent phospholipid-binding protein family. Members of these family, share a common core domain, but each has a unique N-terminal tail that imparts its functional specificity. It is believed that phosphorylation of this region in annexin I regulates its functions.

Annexin I has been implicated in regulating phospholipid vesicle aggregation, mediating inflammatory response, and inhibiting the activity of phospholipase A2. Additionally, it has been found that the 10kDa protein S100C influences annexin I's activity by binding to the N-terminal 13 residues of annexin in a manner similar to that of the annexin II/p11 complex.

Immunocytochemical detection of Annexin I represents a simple and highly sensitive and specific (100%) method for the diagnosis of hairy cell

leukaemia. It has been reported that Annexin A1 is overexpressed in breast carcinomas, hepatocellular carcinoma, pancreatic and pituitary adenomas and downregulated in oesophageal, endometrial and prostate carcinoma.

**IHC POSITIVE CONTROL:** Tonsil or spleen

**VISUALIZATION:** Cell cytoplasm

### IHC RECOMMENDED PROCEDURE:

- 4µm thick section should be taken on charged slides; dry overnight at 60°C
- Deparaffinise, rehydrate and HIER (heat induced epitope retrieval) – boil tissue in the Pt Module using Master Diagnóstica EDTA buffer pH8<sup>3</sup> for 20 min at 95°C. Upon completion rinse with 3-5 changes of distilled or deionised water followed by cooling at RT for 20 min
- Endogenous peroxidase block - Blocking for 10 minutes at room temperature using peroxidase solution (ref. MAD-021540Q-125)
- Primary antibody: incubate for 10 minutes [The antibody dilution (when concentrated) and protocol may vary depending on the specimen preparation and specific application. Optimal conditions should be determined by the individual laboratory]
- For detection use Master Polymer Plus Detection System (HRP) (DAB included; ref. MAD-000237QK)
- Counterstaining with haematoxylin and final mounting of the slide

**STORAGE AND STABILITY:**  up to 18 months;  stored at 2-8°C. Do not freeze.

### WARNINGS AND PRECAUTIONS:

1. Avoid contact of reagents with eyes and mucous membranes. If reagents come into contact with sensitive areas, wash with copious amounts of water.
2. This product is harmful if swallowed.
3. Consult local or state authorities with regard to recommended method of disposal.
4. Avoid microbial contamination of reagents.

### SAFETY RECOMMENDATIONS

This product is intended for laboratory professional use only. The product is NOT intended to be used as a drug or for domestic purposes. The current version of the Safety Data Sheet for this product can be downloaded by searching the reference number at

<sup>1</sup> These references are for presentation in vials of Low Density Polyethylene (LDPE) dropper. In case the products are used in automated stainers, a special reference is assigned as follows:

- / L: Cylindrical screw-cap vials (QD-3 / L, QD-7 / L, QD-12 / L).

- / N: Polygonal screw-cap vials (QD-3 / N, QD-7 / N, QD-12 / N).

For different presentations (references / volumes) please contact the supplier.

<sup>2</sup> For Technical specifications for MD-Stainer, please contact your distributor.

<sup>3</sup> Ref: MAD-004072R/D



## BIBLIOGRAPHY

1. Neild GH, Rodriguez-Justo M, Wall C, Connolly JO, Masaki T, Tokuda M, Ohnishi M, Watanabe S, Fujimura T, Miyamoto K, Itano T, Matsui H, Arima K, Shirai M, Maeba T, Sogawa K, Konishi R, Taniguchi K, Hatanaka Y, Hatase O, Nishioka M. Enhanced expression of the protein kinase substrate annexin in human hepatocellular carcinoma. *Hepatology*; **24**:72-81. 1996.
2. Rand JH. The annexinopathies: a new category of diseases. *Biochim. Biophys. Acta*; **1498**: 169-173. 2000
3. Rothhut B. Participation of annexins in protein phosphorylation. *Cell Mol. Life Sci.* 1997; **53**: 522-526.
4. Ahn SH, Sawada H, Ro JY, Nicolson GL. Differential expression of annexin I in human mammary ductal epithelial cells in normal and benign and malignant breast tissues. *Clin Exp Metastasis*; **15**: 151-156. 1997.
5. Pawletz CP, Ornstein DK, Roth MJ, Bichsel VE, Gillespie JW, Calvert VS, Vocke CD, Hewitt SM, Duray PH, Herring J, Wang QH, Hu N, Linehan WM, Taylor PR, Liotta LA, Emmert-Buck MR, Petricoin EF 3rd. Loss of annexin I correlates with early onset of tumorigenesis in esophageal and prostate carcinoma. *Cancer Res*; **60**: 6293-6297. 2000.
6. Da J, Meng X, Wang P, Yang Z, Zhu Y. Significance on expressions of Annexin-I and its correlative gene proteins in endometrial hyperplasia, atypical hyperplasia and endometrial carcinoma. *Zhonghua Binglixue Zazhi*; **30**: 256-259. 2001.
7. Kang JS, Calvo BF, Maygarden SJ *et al.* Dysregulation of annexin I protein expression in high-grade prostatic intraepithelial neoplasia and prostate cancer. *Clin Cancer Res*; **8**: 117-123. 2002.
8. Xin W, Rhodes DR, Ingold C, Chinnaiyan AM, Rubin MA. Dysregulation of the annexin family protein family is associated with prostate cancer progression. *Am J Pathol*; **162**: 255-261. 2003.
9. Falini B, Tiacci E, Liso A, Basso K, Sabattini E, Pacini R, Foa R, Pulsoni A, Dalla Favera R, Pileri S. Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). *Lancet*; **363**(9424): 1869-1870. 2004.
10. Mulla A, Christian HC, Solito E, Mendoza N, Morris JF, Buckingham JC. Expression, subcellular localization and phosphorylation status of annexins 1 and 5 in human pituitary adenomas and a growth hormone-secreting carcinoma. *Clin Endocrinol*; **60**: 107-119. 2004.
11. Patton K T, Chen H M, Joseph L & Yang X J. Decreased annexin I expression in prostatic adenocarcinoma and in high-grade prostatic intraepithelial neoplasia. *Histopathology*; **47**: 597-601. 2005.